DRD1 Gene Polymorphism Predict Therapeutic Responses in Patients With Bipolar Mania Treated by Combination of Lithium and Olanzapine

Abstract

Objective To explore the correlation between DRD1 gene rs686 and rs4532 polymorphism and bipolar mania episode and therapeutic effect. Methods 60 patients with bipolar mania and 40 normal healthy person as the control group were collected, and the DRD1 gene rs686 and rs4532 polymorphism were tested.The difference of rs4532 and rs686 polymorphism and normal control group was compared and correlated to efficacy of treatment with lithium carbonate combined with olanzapine in patients with bipolar mania by YMRS, HAMD and HAMA assessment in the 2nd, 4th, 6th and 8th weekend. Results The no statistical significance for the polymorphism difference of DRD1 gene polymorphism of rs686 and rs4532 between patients with bipolar mania and normal control. The patients group is divided into AA group and AG + GG group according to different genotypes of rs686, and also is divided into CC + CT group and TT group according to different genotypes of rs4532.At 8th weekend, YMRS score of AA group higher than that of AG + GG group (8.34 ± 1.23 vs 7.38 ± 1.20P < 0.05). The patient's early effective response rate (EERR,YMRS 2nd weekend reduction rate > 25%) and remission rate( RR,YMRS 8th weekend reduction rate ≥ 80%) are higher that in AA group. The no similar difference of rs4532 was found. Conclusion There is a correlation between DRD1 gene rs686 and the therapeutic effect of manic patient. The EERR and RR of rs686 genotype AG + GG group is higher than that of the AA group, suggesting that patients who may contain G alleles can obtain better treatment results.